INDV Quote, Financials, Valuation and Earnings

Pfizer Inc. has a net margin of 13.38% compared to Indivior PLC's net margin of 21.32%. Indivior PLC's return on equity of 14.29% beat Pfizer Inc.'s return on equity of 10.84%.

Indivior PLC has a consensus price target of $37.86, signalling upside risk potential of 9.41%. On the other hand Pfizer Inc. has an analysts' consensus of $29.04 which suggests that it could grow by 13.57%. Given that Pfizer Inc. has higher upside potential than Indivior PLC, analysts believe Pfizer Inc. is more attractive than Indivior PLC.

Indivior PLC has a beta of 1.102, which suggesting that the stock is 10.185% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Indivior PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.73% to investors and pays a quarterly dividend of $0.43 per share. Indivior PLC pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Indivior PLC quarterly revenues are $314M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Indivior PLC's net income of $42M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Indivior PLC's price-to-earnings ratio is 34.45x while Pfizer Inc.'s PE ratio is 14.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Indivior PLC is 3.70x versus 2.32x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Travere Therapeutics, Inc. has a net margin of 13.38% compared to Indivior PLC's net margin of 15.59%. Indivior PLC's return on equity of 14.29% beat Travere Therapeutics, Inc.'s return on equity of -263.9%.

Indivior PLC has a consensus price target of $37.86, signalling upside risk potential of 9.41%. On the other hand Travere Therapeutics, Inc. has an analysts' consensus of $41.5000 which suggests that it could grow by 19.08%. Given that Travere Therapeutics, Inc. has higher upside potential than Indivior PLC, analysts believe Travere Therapeutics, Inc. is more attractive than Indivior PLC.

Indivior PLC has a beta of 1.102, which suggesting that the stock is 10.185% more volatile than S&P 500. In comparison Travere Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.435%.

Indivior PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Travere Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Indivior PLC pays -- of its earnings as a dividend. Travere Therapeutics, Inc. pays out -- of its earnings as a dividend.

Indivior PLC quarterly revenues are $314M, which are larger than Travere Therapeutics, Inc. quarterly revenues of $164.9M. Indivior PLC's net income of $42M is higher than Travere Therapeutics, Inc.'s net income of $25.7M. Notably, Indivior PLC's price-to-earnings ratio is 34.45x while Travere Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Indivior PLC is 3.70x versus 7.26x for Travere Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viatris, Inc. has a net margin of 13.38% compared to Indivior PLC's net margin of -3.41%. Indivior PLC's return on equity of 14.29% beat Viatris, Inc.'s return on equity of -21.75%.

Indivior PLC has a consensus price target of $37.86, signalling upside risk potential of 9.41%. On the other hand Viatris, Inc. has an analysts' consensus of $12.1250 which suggests that it could grow by 11.85%. Given that Viatris, Inc. has higher upside potential than Indivior PLC, analysts believe Viatris, Inc. is more attractive than Indivior PLC.

Indivior PLC has a beta of 1.102, which suggesting that the stock is 10.185% more volatile than S&P 500. In comparison Viatris, Inc. has a beta of 0.843, suggesting its less volatile than the S&P 500 by 15.721%.

Indivior PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viatris, Inc. offers a yield of 4.43% to investors and pays a quarterly dividend of $0.12 per share. Indivior PLC pays -- of its earnings as a dividend. Viatris, Inc. pays out 90.63% of its earnings as a dividend. Viatris, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Indivior PLC quarterly revenues are $314M, which are smaller than Viatris, Inc. quarterly revenues of $3.8B. Indivior PLC's net income of $42M is higher than Viatris, Inc.'s net income of -$128.2M. Notably, Indivior PLC's price-to-earnings ratio is 34.45x while Viatris, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Indivior PLC is 3.70x versus 0.91x for Viatris, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xenetic Biosciences, Inc. has a net margin of 13.38% compared to Indivior PLC's net margin of -49.65%. Indivior PLC's return on equity of 14.29% beat Xenetic Biosciences, Inc.'s return on equity of -59.39%.

Indivior PLC has a consensus price target of $37.86, signalling upside risk potential of 9.41%. On the other hand Xenetic Biosciences, Inc. has an analysts' consensus of -- which suggests that it could grow by 1552.89%. Given that Xenetic Biosciences, Inc. has higher upside potential than Indivior PLC, analysts believe Xenetic Biosciences, Inc. is more attractive than Indivior PLC.

Indivior PLC has a beta of 1.102, which suggesting that the stock is 10.185% more volatile than S&P 500. In comparison Xenetic Biosciences, Inc. has a beta of 2.398, suggesting its more volatile than the S&P 500 by 139.837%.

Indivior PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenetic Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Indivior PLC pays -- of its earnings as a dividend. Xenetic Biosciences, Inc. pays out -- of its earnings as a dividend.

Indivior PLC quarterly revenues are $314M, which are larger than Xenetic Biosciences, Inc. quarterly revenues of $1M. Indivior PLC's net income of $42M is higher than Xenetic Biosciences, Inc.'s net income of -$509.9K. Notably, Indivior PLC's price-to-earnings ratio is 34.45x while Xenetic Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Indivior PLC is 3.70x versus 1.31x for Xenetic Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.